Clinical trials
Neuroendocrine Cancer clinical trials
Below are recruiting neuroendocrine cancer clinical trials, each written for real people, not researchers. We’re tracking 123 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT00830557Recruiting
Share information and donate tissue samples for pancreatic illnesses
This study collects health information and tissue samples from people with pancreatic cancer or other pancreatic conditions. Your participation may help researchers better understand these diseases and improve future care.
Phoenix, ArizonaAges 18 years+ - NCT03048266Recruiting
Testing genes and blood chemistry in MEN1 pancreatic tumors
This study looks at blood chemistry (metabolomics) and genetic information in people who have MEN1, especially if they are being evaluated for pancreatic neuroendocrine tumors. It may help doctors better diagnose these tumors by finding patterns in test results.
Houston, TexasAges Any age - NCT04339036RecruitingPhase 2
CapTem plus Y-90 for liver-spread neuroendocrine tumors
This Phase 2 study tests whether combining capecitabine/temozolomide (“CapTem”) with Y-90 treatment can shrink neuroendocrine tumor (NET) spread in the liver. It may help people whose tumor is mostly in the liver and cannot be fully removed with surgery.
La Jolla, CaliforniaAges 18 years+ - NCT04723095Recruiting
Cervical neuroendocrine cancer registry for past and present patients
This study builds a registry (a secure database) of people who have had cervical neuroendocrine cancer, including small cell or large cell types. It helps researchers learn more about these cancers and may improve future care and research planning.
Houston, TexasAges Any age - NCT06607692RecruitingPhase 1/Phase 2
LuPARPed: Targeted radiation plus olaparib for certain childhood cancers
This trial tests a combination of a radioactive drug (Lutathera) and a targeted pill (olaparib) for children and teens whose solid tumors have come back or not responded to treatment and show high levels of a specific receptor (SSTR) on scans. The goal is to see if this two-drug approach can shrink tumors or stop them from growing.
Boadilla del Monte, MadridAges 3 years+ - NCT07439757Recruiting
Using AI to Guide Care for Pancreatic Conditions
This study uses artificial intelligence (AI) to help doctors make better decisions for people with suspected pancreatic conditions. If you are already getting a special CT scan, the AI will analyze the images to see if it can improve diagnosis and treatment planning.
ShanghaiAges 18–80 - NCT04954820RecruitingPhase 2
Second round Lutathera for intestinal NET after regrowth
This Phase 2 study looks at whether giving Lutathera again (a second round) can control an intestinal neuroendocrine tumor (NET) that came back or progressed after the first treatment. It mainly targets adults whose scan shows tumors still take up the right “target” signal and who previously benefited for at least 12 months.
AngersAges 18 years+ - NCT06788886Recruiting
Breathing practice for brain and mental health in cancer and other illnesses
This study tests a simple breathing practice to see if it can improve brain health and mental well-being for people with cancer, multiple sclerosis, or their caregivers. You will do light exercises and answer questionnaires, and some participants will also have an MRI brain scan.
Rochester, MinnesotaAges 18–85 - NCT06788938RecruitingPhase 2
Tarlatamab for advanced DLL3-positive tumors
This trial tests a drug called tarlatamab for people with advanced cancers that have a specific protein called DLL3. It aims to see if this treatment can help when other treatments have stopped working.
Davis, CaliforniaAges 18 years+ - NCT06282016Recruiting
Risk factors for neuroendocrine tumors in Bavaria
This study looks at medical records from people in Bavaria to find out what might increase the risk of developing neuroendocrine neoplasms (a rare type of tumor). By reviewing routine health data, researchers hope to discover early signs or risk factors that could help with future detection and care.
Nuremberg, BavariaAges Any age - NCT04924075RecruitingPhase 2
Belzutifan for cancers linked to VHL or HIF-2α changes
This Phase 2 study tests belzutifan (MK-6482) to treat certain advanced cancers caused by specific gene or disease changes, including VHL-related tumors and HIF-2α related tumors. It may help shrink tumors or slow their growth in people whose cancer matches these genetic or disease patterns.
Los Angeles, CaliforniaAges 12 years+ - NCT04086485RecruitingPhase 1/Phase 2
Lu-177 dotatate plus olaparib for inoperable neuroendocrine tumors
This study tests whether combining Lu-177 dotatate (a targeted radiation treatment) with olaparib (a targeted pill) can shrink or slow growth of inoperable gastroenteropancreatic neuroendocrine tumors. It’s designed for tumors that show the right “targets” on a special scan and that have started to progress despite standard care.
Bethesda, MarylandAges 18–100 - NCT06333314RecruitingPhase 2
Dostarlimab for advanced dMMR/MSI cancers (not colorectal or endometrial)
This trial tests a drug called dostarlimab for people with certain advanced cancers that have a specific genetic feature (dMMR/MSI-H). The goal is to see if it helps shrink or control the cancer in people who haven't had other treatments yet.
AngersAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Birmingham, AlabamaAges 18 years+ - NCT06427798RecruitingPhase 1/Phase 2
Radioactive drug for previously treated gut or adrenal tumors
This trial tests a new radioactive drug, [212Pb]VMT-alpha-NET, that targets a receptor found on some tumor cells. It is for people with certain gut or adrenal gland tumors that have already been treated with a similar therapy but are still growing.
Bethesda, MarylandAges 18–120 - NCT05687123RecruitingPhase 1
Adding sunitinib to Lutathera for pancreatic neuroendocrine tumors
This early-phase study tests whether adding sunitinib (a targeted pill) to Lutathera (a radioactive treatment) works better for people with advanced pancreatic neuroendocrine tumors. It also checks safety, since this combination has not been widely studied yet.
Duarte, CaliforniaAges 18 years+ - NCT06176989RecruitingPhase 2
Enasidenib for IDH2-mutated sinonasal and skull base tumors
This trial tests an oral targeted therapy called enasidenib for people with rare head and neck cancers that have an IDH2 gene mutation. The goal is to see if this drug can shrink or slow the growth of these tumors.
Bethesda, MarylandAges 18–120 - NCT05910177RecruitingPhase 2
Pre-surgery treatment for cervical neuroendocrine cancer with immunotherapy
This Phase 2 trial tests giving camrelizumab plus chemotherapy (etoposide and cisplatin) before surgery for certain cervical neuroendocrine cancers. It aims to shrink the tumor and improve outcomes by treating cancer early rather than waiting until after surgery.
Fuzhou, FujianAges 18–75 - NCT06519500Recruiting
Growing tumor models from gastrointestinal neuroendocrine tumor surgery
This study takes tumor tissue from people having surgery for a certain type of gut or pancreas cancer (neuroendocrine tumors). The tissue is used to grow tiny 3D models called organoids in the lab, which can help researchers learn more about the tumor and find better treatments.
RomeAges 18 years+ - NCT06041009Recruiting
Pancreatic cancer screening with a new enzyme test
This study is testing if measuring a substance called elastase-1, along with standard tests, can help find pancreatic cancer earlier. It may benefit people who already have signs of pancreatic disease or are at high risk.
Jinan, ShandongAges 18 years+ - NCT06202066RecruitingPhase 2
Temozolomide plus Survivin Vaccine for Growing Neuroendocrine Tumors
This trial tests a combination of a chemotherapy drug (temozolomide) and a vaccine (SurVaxM) that targets a protein called survivin found in some neuroendocrine tumors. It is for patients whose tumors have grown after at least one prior treatment, with the goal of slowing or stopping further growth.
Buffalo, New YorkAges 18 years+ - NCT06016855RecruitingPhase 4
Surgery before radiation therapy for neuroendocrine tumors
This trial tests if removing as much tumor as possible through surgery before a targeted radiation therapy (PRRT) can help people with well-differentiated neuroendocrine tumors that have spread to the liver. The goal is to see if this approach works better than radiation therapy alone.
Nashville, TennesseeAges 18 years+ - NCT05773274RecruitingPhase 2
Retreating with 177Lu-DOTATATE radiation versus usual treatment
This trial tests whether repeating a targeted radioactive treatment (177Lu-DOTATATE) works better than standard options in people with metastatic gastroenteropancreatic neuroendocrine tumors. It may help by controlling tumor growth after the first round of this therapy stops working.
Birmingham, AlabamaAges 18 years+ - NCT07366658RecruitingPhase 1
Experimental therapy for neuroendocrine tumors that did not respond to treatment
This trial tests an experimental therapy (NEUK203-13) for people with neuroendocrine tumors, including small cell lung cancer, that have not responded to or stopped responding to standard treatments. It aims to see if the drug is safe and to look for early signs that it might shrink tumors, especially in people whose tumors have a specific marker called DLL3.
BeijingAges 18–75
Hear when a new Neuroendocrine Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for neuroendocrine cancer?
- Yes. Clin2 currently lists 123 recruiting neuroendocrine cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a neuroendocrine cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a neuroendocrine cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.